CD19 and acute lymphoblastic leukemia: This finding may have therapeutic implications, since CD19-negative myeloid lineage relapses after blinatumomab have been observed in p210 Ph+-ALL patients as a result of the selection of preexisting CD19-negative malignant progenitor of myeloid origin (159).